OncoPrecision's ONC001 to Transform Cancer Treatment at ASH Meeting
- OncoPrecision's ONC001 targets CD64 receptors in aggressive blood cancers, showcasing its potential at the ASH Annual Meeting.
- The therapy aims to overcome monocyte-driven resistance in chronic myelomonocytic leukemia and acute myeloid leukemia.
- ONC001's presentation highlights OncoPrecision's commitment to innovation and advancing treatment options for challenging blood cancer patients.
OncoPrecision Pioneers Novel Cancer Therapy with ONC001 Presentation at ASH Meeting
OncoPrecision Corporation, a cutting-edge translational therapeutics firm, makes significant strides in the fight against aggressive blood cancers with its development candidate, ONC001. This innovative antibody-drug conjugate (ADC) is designed to specifically target the CD64 receptor, which is prevalent in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) subtypes M4 and M5, particularly in resistant cases. The company announces that ONC001 will receive an oral presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, scheduled for December 6-9, 2025. This selection underscores the therapy's potential to address critical resistance mechanisms that challenge current treatment options.
Developed through OncoPrecision's proprietary discovery engine, which leverages patient-derived biology and AI-driven high-throughput screening, ONC001 represents a novel approach to overcoming the monocyte-driven resistance commonly seen in these aggressive cancers. Co-Founder and Chief Scientific Officer Dr. Gastón Soria will present preclinical data demonstrating ONC001's selective engagement with patient-derived CMML and AML cells, showcasing its robust efficacy even against samples that have resisted existing therapies. This data not only highlights the unique capabilities of ONC001 but also positions OncoPrecision as a leader in the innovation of cancer therapeutics targeting previously overlooked mechanisms.
The significance of ONC001's oral presentation at ASH cannot be overstated, as it allows OncoPrecision to showcase its commitment to advancing treatment options for patients with challenging blood cancers. Co-Founder and CEO Tarek Zaki emphasizes that this development could significantly change the therapeutic landscape for patients suffering from these conditions, where effective treatments are currently limited. Dr. Soria notes that, despite the recognition of CD64 as a critical biomarker for monocytic leukemia, there remain no approved or clinical-stage therapies effectively targeting it. This positions ONC001 as a groundbreaking innovation, potentially paving the way for new therapeutic strategies in the field of oncology.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

